Benfogamma 150 mg 30 pcs

Benfothiamine is a fat-soluble derivative of thiamine. Thiamine is converted into active thiamine pyrophosphate and as a coenzyme, is included in pyruvate decarboxylase, alpha-ketoglutarate decarboxylase complexes, which participate in the oxidative decarboxylation of pyruvic and alpha-ketoglutaric acid; transketolase – pentose phosphate shunt enzyme.

Pharmacokinetics

Absorption is high, throughout the small intestine. Before absorption it is released from bound state by digestive enzymes. After 15 min it is detected in blood and after 30 min – in other tissues. Blood concentrations are relatively low, with free thiamine circulating mainly in plasma, its phosphorus esters in erythrocytes and leukocytes. Phosphorylation occurs in the liver.

The most active phosphorus ester is thiamindiphosphate, which has coenzyme activity. It accumulates mainly in the liver, heart, brain, kidneys, and spleen. 1/2 of the total amount is found in the transverse striated muscle and myocardium and about 40% in the internal organs. It is excreted through the intestine and the kidneys.

Indications

B1 deficiency confirmed by clinical and biochemical studies, developing against the background of:

insufficient and malnutrition (beriberi);
long-term parenteral nutrition, hemodialysis;
chronic alcoholism (alcoholic cardiomyopathy, Wernicke encephalopathy, Korsakoff syndrome);
increased need for vitamin B1.

Polyneuropathy caused by vitamin B1 deficiency. Typical signs of such a deficiency are neurological disorders in the form of neuropathies with sensory disturbances (pain, tingling sensation, loss of sensation in the upper and lower extremities).

Pharmacological effect

Benfotiamine is a fat-soluble derivative of thiamine. Thiamine is converted into active thiamine pyrophosphate and, as a coenzyme, is included in the pyruvate decarboxylase and alpha-ketoglutarate decarboxylase complexes, which are involved in the oxidative decarboxylation of pyruvic and alpha-ketoglutaric acids; transketolase is an enzyme of the pentose phosphate shunt.

Pharmacokinetics

Absorption is high, throughout the small intestine. Before absorption, it is released from its bound state by digestive enzymes. After 15 minutes it is detected in the blood, after 30 minutes – in other tissues. The concentration in the blood is relatively low, while predominantly free thiamine circulates in the plasma, and its phosphorus esters circulate in erythrocytes and leukocytes. Phosphorylation occurs in the liver.

The most active phosphorus ester is thiamine diphosphate, which has coenzyme activity. It accumulates mainly in the liver, heart, brain, kidneys, and spleen. 1/2 of the total amount is found in striated muscles and myocardium and about 40% in internal organs. Excreted through the intestines and kidneys.

Special instructions

In elderly people, no adverse reactions other than the above were noted.
It is not recommended to take a double dose of the drug if the previous dose was missed.
In Wernicke encephalopathy, the administration of dextrose should be preceded by thiamine.

Impact on the ability to drive vehicles and machinery
There is no data on the effect of the drug on the ability to drive vehicles and machines when used in therapeutic doses.

Active ingredient

Benfotiamine

Composition

1 tablet contains:

active ingredient:

benfotiamine 150 mg,

excipients:

microcrystalline cellulose 122.0 mg,

povidone K-30 8.0 mg,

fatty acid glycerides 5.0 mg,

colloidal silicon dioxide 7.0 mg,

carmellose sodium 3.0 mg,

talc 10.0 mg;

shell composition:

shellac 3.0 mg,

sucrose 70.875 mg,

calcium carbonate 66.479 mg,

talc 41.314 mg,

acacia gum 10.155 mg,

corn starch 7.340 mg,

titanium dioxide 10.932 mg,

colloidal silicon dioxide 4.404 mg,

povidone K-30 6.210 mg,

macrogol-6000 1.597 mg,

glycerol 85% 2.262 mg,

polysorbate 80 0.133 mg,

mountain glycol wax 0.300 mg

Pregnancy

Pregnancy is a contraindication for the use of the drug.

Contraindications

Increased individual sensitivity to the components of the drug,
sucrose/isomaltose deficiency,
fructose intolerance, glucose-galactose malabsorption,
1st period of pregnancy,
childhood.

Side Effects

Allergic reactions: angioedema, urticaria, itching.

Interaction

Thiamine weakens the effect of depolarizing muscle relaxants (suxamethonium iodide, etc.) and is inhibited by fluorouracil.
Ethanol slows the rate of absorption of thiamine after oral administration.

Overdose

An overdose of Benfogamma 150 has not been observed to date.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

5 years

Manufacturer

Dragenopharm Apotheker Püschl GmbH, Germany